3648 results for «2437»
3648 results
PRISM-PCI - From clarity to cure
20 May 2026 – From EuroPCR 2026
PRISM-PCI offers cutting-edge imaging innovations and treatment strategies aimed at optimizing complex PCI procedures. This session explores the 'leave nothing behind' concept with thin-strut bioresorbable scaffolds and sirolimus drug-coated balloons, updates on ultra thin-strut DES platforms, including the SORT OUT XII trial, and introduces a comprehensive...
The continuum of valvular heart disease: a lifetime management approach
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive perspective on valvular heart disease through the lens of lifetime management, highlighting the need for strategic planning across aortic, mitral, and tricuspid interventions, illustrating how treating one valve can influence the progression and management of others. Gain insights into optimal timing...
Is durability still a topic of concern for TAVI patients? What are the remaining challenges that we need to overcome?
20 May 2026 – From EuroPCR 2026
Examine the clinical relevance of TAVI valve durability and its impact on long-term patient management in aortic stenosis. Review key factors influencing valve performance over time, with a focus on procedural and anatomical determinants of optimal outcomes.
Current concepts and techniques aimed at achieving ideal valve expansion...
Navigating high-thrombus burden in ACS: precision aspiration thrombectomy with CAT RX
21 May 2026 – From EuroPCR 2026
This session explores the challenges of managing high thrombus burden in patients with acute coronary syndromes (ACS), with a focus on precision aspiration thrombectomy using the CAT RX device. Through case-based examples, it provides practical insights into procedural techniques and examines the role of CAT RX...
TAVI vs. surgery - Are the latest long-term data creating a dilemma for aortic stenosis patients?
21 May 2026 – From EuroPCR 2026
This session critically evaluates the latest long-term data comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). It explores differing perspectives between surgeons and interventional cardiologists regarding valve durability and lifetime management, fostering a high-quality debate to achieve consensus within Heart Team discussions...
CathWorks FFRangio: from clinical data to advanced patient care
21 May 2026 – From EuroPCR 2026
Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...
Real world practice inspiring new evidence generation in structural heart
21 May 2026 – From EuroPCR 2026
This LIVE case session showcases real-world clinical practice driving new evidence in structural heart interventions, with a focus on TAVI. It features expert insights into pre-procedural imaging and sizing, treatment strategies, procedural techniques, and post-procedural management. The session also introduces the novel Myval Octapro+ transcatheter heart...
Renal denervation in China: momentum, insights, and evolution
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.
It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal...
The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the emerging metal-free strategy in coronary intervention, combining drug-coated balloons (DCB) and bioresorbable scaffolds (BRS) to support a “leave-nothing-behind” approach to vessel restoration.
It focuses on lesion preparation, scaffold sizing and deployment, and the integration of hybrid therapies to optimise procedural outcomes....
Pulmonary embolism intervention: a turning point in defining success
21 May 2026 – From EuroPCR 2026
This session explores the evolving objectives of pulmonary embolism treatment, highlighting the shift from simple patient stabilisation to a more comprehensive approach to recovery. It introduces the novel Transforming Fixation (TFX) technology and its role in improving catheter stability and access to the pulmonary vasculature. Drawing...
Rethinking stentless PCI strategy - Improving outcomes with Bioadaptor
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores contemporary PCI strategies through the concept of stentless intervention using the Bioadaptor device in complex coronary disease.
It highlights the bioadaptive design features of Bioadaptor and reviews the supporting clinical evidence, with a focus on how this technology may influence procedural outcomes.
The...
How to become a CHAMPION in LAA closure
19 May 2026 – From EuroPCR 2026
This session reviews the latest CHAMPION AF trial data and its implications for left atrial appendage (LAA) closure in patients with atrial fibrillation.
It explores how emerging evidence may influence clinical practice and patient selection, and how LAA closure could evolve across different atrial fibrillation populations.
A recorded...
Disrupting the aorta and valves: the next transcatheter wave
18 May 2026 – From EuroPCR 2026
Delve into the next wave of transcatheter interventions disrupting the aorta and valves. This session covers pioneering minimally invasive ascending aortic repair, novel polymeric aortic valve implants, and innovative devices for tricuspid repair and leaflet replacement.
The Physiology Course - Introduction
18 May 2026 – From EuroPCR 2026
The Physiology Course introduction welcomes participants and provides an overview of the importance of coronary physiology, outlining the program designed in collaboration with EuroPCR.
Management of a patient with complex multivessel disease involving bifurcations
19 May 2026 – From EuroPCR 2026
Complex multivessel coronary disease involving bifurcations requires careful procedural planning, imaging guidance and tailored stent strategies.
This EuroPCR 2026 session combines live educational case with insights from the NAGOMI COMPLEX study to explore contemporary approaches to complex PCI. A key focus is placed on the role of...
Landmark interventional randomised controlled trial data and practice guidelines to transform pulmonary embolism care
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents landmark randomised controlled trial data shaping interventional treatment of pulmonary embolism, with a focus on translating evidence into clinical practice.
It reviews the HI-PEITHO trial and its implications in intermediate-risk acute PE, where ultrasound-assisted catheter-directed thrombolysis (USCDT) reduced the composite endpoint of...
The physiological mindset: foundations every modern operator must own
18 May 2026 – From EuroPCR 2026
This session delves into the fundamental principles governing coronary blood flow regulation, emphasizing coronary autoregulation and the influence of epicardial haemodynamics on vascular morphology. Participants deepen their understanding of coronary physiology beyond formulas, exploring the intersection of physiology and atherosclerosis.
Physiology in the real world: how to measure, when to trust it, what to do?
18 May 2026 – From EuroPCR 2026
This session provides comprehensive insights into coronary physiology assessment tools, emphasizing techniques for reliable haemodynamic measurements and exploring clinical considerations surrounding coronary spasms and myocardial bridges.
Early evidence from a next generation coronary sinus reducer for the treatment of coronary microvascular dysfunction
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents early clinical experience with a next-generation self-expanding nitinol coronary sinus reducer for patients with coronary microvascular dysfunction. It reviews practical aspects of device implantation and discusses initial findings from the SERRA I feasibility study, providing insight into this emerging therapeutic approach....
Rapid fire session on next generation structural heart and valve therapies
18 May 2026 – From EuroPCR 2026
An intensive rapid-fire session presenting the latest advancements in next-generation structural heart and valve therapies, including novel transcatheter systems for aortic and mitral valve repair, innovative solutions for tricuspid regurgitation, and implant-free PFO closure technologies.